Mesothelioma — Ann Oncol

Quoted from


[Annals of Oncology]

W. Weder*

Author Affiliations

Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland

*Correspondence to: Prof. W. Weder, Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; E-mail:;

Malignant pleural mesothelioma continues to be a clinical challenge. The disease is associated with asbestos exposure; its incidence will continue to increase in regions even though the commercial use of asbestos has been banned, and is certain to continue to contribute to cancer mortality in regions of the word lacking worker protection and persisting with its commercial use. It will depend on political actions and the will of governments to change this situation [1]. Once diagnosed with pleural mesothelioma, patients nearly invariably die of the disease. Advances have been made in the immunohistochemical diagnosis of the disease allowing a firm diagnosis in most patients. While some benefit of chemotherapy for advanced disease has been established, many other aspects of treatment continue to be controversial, in particular in regard to surgery and radiotherapy. However, the best survival data are reported from groups using multimodality treatment including neo- or adjuvant chemotherapy and extrapleural pneumonectomy (EPP). Over the past few years several review articles have dealt with pleural mesothelioma [25] and recently the new European Respiratory Society/European Society of Thoracic Surgeons guidelines have been published [6].


[Article continues at original source]

Speak Your Mind


Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
Tel: (800) 426-9535
Disclaimer and Copyright